MRNA injection aims to turn back the clock on aging
NCT ID NCT07544420
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an mRNA drug called aKL003 that instructs cells to produce alpha klotho, a protein linked to longevity. About 21 healthy adults aged 50-90 will receive two injections four weeks apart. The main goal is to check safety and whether the protein levels rise in the blood.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- alpha klotho mRNA (aKLmRNA, AKL003) in lipid nanoparticles
- What this could lead to
- If successful, this could point toward a treatment that slows or reverses aspects of aging by increasing alpha klotho protein levels.
- What could go wrong
- This is a very early Phase 1b safety trial with only 21 healthy volunteers. It is not designed to prove any anti-aging effect, and the treatment may fail to raise protein levels or cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGING are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GARM
Roatán, Bay Islands, 34101, Honduras
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your heart hold the key to Alzheimer's prevention?
- The aging Body's hidden water shift: a new study investigates
- Rewiring the veteran brain: could visual training counteract cognitive decline?
- Can a simple walk test reveal hidden health risks in aging?
- A handful of walnuts a day: could it keep the aging mind sharp?
- Shining a light on brain aging: could NIR boost memory?